ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research  By  cover art

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

By: American College of Cardiology
  • Summary

  • The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.
    American College of Cardiology Foundation. All rights reserved.
    Show more Show less
Episodes
  • ARISE-HF Primary Results: Selective Aldose Reductase Inhibitor For Diabetic Cardiomyopathy
    Apr 23 2024

    Heart failure is an increasingly recognized complication in chronic diabetes that may be caused by a number of processes including direct effects of hyperglycemia on the heart muscle. So-called diabetic cardiomyopathy may affect up to 20% of people with chronic diabetes and represents a unique target for treatment.

    In this interview, James Januzzi, MD, FACC, and Alison L. Bailey, MD FACC discuss the primary results from the ARISE-HF study: Selective Aldose Reductase Inhibitor For Diabetic Cardiomyopathy.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Show more Show less
    12 mins
  • The Future of Cardiology - Value-Based Care, Private Equity and the Practice Landscape
    Apr 16 2024

    It's becoming increasingly evident that alongside top-notch clinical expertise, the CV specialist of the future must be surrounded by a multi-talented, diverse team to provide optimal patient care. In addition, it is crucial that the clinician and CV organization engage in non-clinical competencies to enhance value for patients, the healthcare system, and society. MedAxiom and ACC collaborate synergistically toward achieving these goals.

    In this interview, Jerry Blackwell MD, MBA, FACC and Joseph E. Marine MD, MBA, FACC, discuss The Future of Cardiology - Value-Based Care, Private Equity and the Practice Landscape.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Show more Show less
    12 mins
  • EMPACT-MI Results: Empagliflozin After Acute Myocardial Infarction
    Apr 9 2024

    Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart failure continues to be unacceptably high. No intervention in 2 decades has been shown to improve this risk.

    In this interview, Javed Butler, MD, MPH, MBA, and Sun Moon Kim, MD, FACC, discuss the results of the EMPACT-MI trial.

    Show more Show less
    11 mins

What listeners say about ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.